Drug Profile
Multiple sclerosis vaccine - ImmuLogic
Latest Information Update: 16 Jan 2001
Price :
$50
*
At a glance
- Originator ImmuLogic Pharmaceutical
- Class Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 16 Jan 2001 Discontinued-Preclinical for Multiple sclerosis in USA (SC)
- 12 Feb 1997 New profile
- 12 Feb 1997 Preclinical development for Multiple sclerosis in USA (SC)